Orphan Drug development specialist TMC Pharma has appointed Gordon Cameron to its board as a non-executive director.
Mr Cameron has 25 years’ board-level experience in biotech and pharmaceutical services sectors. He started his career with EY, then spent several years in investment banking at Rothschild before becoming CFO, and then CEO, of international vaccine company Acambis.
For the past 15 years, Mr Cameron has been CFO of Quotient Sciences, an international Contract Development and Manufacturing Organization and Clinical Research Organization.
In 2004, he was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry.
Julie Matthews, chief executive officer of TMC Pharma, said that the new appointment would “enhance our strategic capability and tactical execution as we consolidate our position as a global leader in the Orphan Drug development market.”
Mr Cameron, added: “TMC Pharma has established itself as a significant player in a fast-growing segment of the global pharmaceutical industry. I am excited to join its board and support Julie and the team as they continue to expand in the UK and the rest of the world.”